Yahoo India Web Search

Search results

  1. Dr. Reddys Laboratories, a leading multinational pharmaceutical company based in India and overseas, committed to providing affordable and innovative medicines for healthier lives.

  2. Dr. Reddy's Laboratories is an Indian multinational pharmaceutical company based in Hyderabad. The company was founded by Kallam Anji Reddy, who previously worked in the mentor institute Indian Drugs and Pharmaceuticals Limited. [2] Dr.

  3. Dr. Reddys Laboratories commenced its generics business in India in 1986 and is today a trusted name in the healthcare industry consistently serving the needs of millions of patients with high quality, affordable and innovative medicines across therapy areas.

  4. Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY) is a global pharmaceutical company headquartered in Hyderabad, India. Established in 1984, we are committed...

  5. 22 hours ago · India Business News: HYDERABAD: Dr Reddy’s Laboratories Ltd has entered into a non-exclusive patent licensing pact with Japan’s Takeda Pharmaceutical Company Limited (Take.

  6. Dr. Reddy's Laboratories | 1,194,962 followers on LinkedIn. We accelerate access to affordable and innovative medicines because Good Health Can’t Wait. | Dr. Reddys Laboratories Ltd. (BSE ...

  7. Dr. Reddys Laboratories. 2,621 followers. 12mo. Just finished "Leading with Innovation" by Anil Gupta, and Haiyan Wang! Check it out: https://lnkd.in/dPk5yk-B #innovationmanagement....

  8. 9 hours ago · Welcome to the Dr. Reddy's Laboratories Stock Liveblog, your real-time source for the latest updates and comprehensive analysis on a prominent stock. Dive into the current details of Dr. Reddy's Laboratories, including: Last traded price 6660.0, Market capitalization: 111233.7, Volume: 332, Price-to-earnings ratio 19.94, Earnings per share 334.35. Our liveblog offers a complete overview of Dr. Reddy's Laboratories through a blend of fundamental and technical indicators. Stay informed about ...

  9. 8 hours ago · Dr. Reddy's Laboratories said that it has entered into a non-exclusive patent licensing agreement with Takeda Pharmaceutical Company to commercialise Vonoprazan tablets in India. Vonoprazan is a novel, orally active potassium competitive acid blocker (PCAB), used to treat reflux esophagitis and other acid peptic disorders.

  10. We accelerate access to affordable and innovative medicines because Good Health Can’t Wait. | Dr. Reddys Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY) is a...